

ELEVATE

Formulary Updates to Elevate Plans
(Bronze HDHP/Standard,
Silver Select/Standard,
Gold Select/Standard)

P&T/Formulary Committee Actions
4Q2020 (Effective January 1, 2021)

4Q20 Formulary Actions													
Drug							Formulary Status		Utilization Management		Rationale of Changes		
							Marketplace (HIEX)		Marketplace (HIEX)				
Category	Brand Name	Generic Name	Strength	Dosage Form	Route	Brand Status	Current Status	Action	Current Status	Action	COMMERCIAL	Optional Benefit Exclusion	Client Communication - Marketplace (HIEX)
ASTHMA AND COPD	BREZTRI AEROSPHERE	BUDESONIDE/GLYCOPYR/FORMOTEROL	160-9-4.8	HFA AER AD	INHALATION	SSB	3	C=2	QL	S=QL	Trade Relations Strategy		
ASTHMA AND COPD	NUCALA	MEPOLIZUMAB	100 MG	VIAL	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)	
ASTHMA AND COPD	NUCALA	MEPOLIZUMAB	100 MG/ML	SYRINGE	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy		
ASTHMA AND COPD	NUCALA	MEPOLIZUMAB	100 MG/ML	AUTO INJECT	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy		
ASTHMA AND COPD	SYMBICORT	BUDESONIDE/FORMOTEROL FUMARATE	80-4.5 MCG	HFA AER AD	INHALATION	SSB	2	S=2	QL	C=QL	Clinical/Safety Strategy		QL: LIMITED TO 40.8 GM PER 30 DAYS
ASTHMA AND COPD	DULERA	MOMETASONE/FORMOTEROL	50MCG-5MCG	HFA AER AD	INHALATION	SSB	3	S=3	QL ST	S=ST C=QL	Clinical/Safety Strategy		QL: LIMITED TO 39 GM PER 25 DAYS
BEHAVIORAL HEALTH - ANTIDEPRESSANTS	SPRAVATO	ESKETAMINE HCL	28 MG	SPRAY	NASAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy		
BEHAVIORAL HEALTH - ANTIDEPRESSANTS	SPRAVATO	ESKETAMINE HCL	56 MG	SPRAY	NASAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy		
BEHAVIORAL HEALTH - ANTIDEPRESSANTS	SPRAVATO	ESKETAMINE HCL	84 MG	SPRAY	NASAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy		
BEHAVIORAL HEALTH - OTHER	XYREM	SODIUM OXYBATE	500 MG/ML	SOLUTION	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy		

BEHAVIORAL HEALTH - OTHER	XYWAV	SODIUM,CALCIUM, MAG,POT OXYBATE	0.5G/ML	SOLUTION	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy		
BEHAVIORAL HEALTH - OTHER	WAKIX	PITOLISANT HCL	17.8 MG	TABLET	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy		
BEHAVIORAL HEALTH - OTHER	WAKIX	PITOLISANT HCL	4.45 MG	TABLET	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy		
CARDIOVASCULAR DISEASE - HYPERTENSION	CONJUPRI	LEVAMLODIPINE MALEATE	2.5 MG	TABLET	ORAL	SSB	3	S=3	PA	C=PA	Clinical/Safety Strategy		
CARDIOVASCULAR DISEASE - HYPERTENSION	CONJUPRI	LEVAMLODIPINE MALEATE	5 MG	TABLET	ORAL	SSB	3	S=3	PA	C=PA	Clinical/Safety Strategy		
DERMATOLOGY - ANTIINFLAMMATORY	DESONIDE	DESONIDE	0.05 %	GEL (GRAM)	TOPICAL	GENERIC/MSB	1	S=1	NONE	A=ST	Low Net Cost Strategy		ST: TRIAL OF 1 OF THE FOLLOWING: FLUTICASONE 0.05% CRM, TRIAMCINOLONE (0.1% LTN, 0.025% OINT), DESONIDE 0.05% OINT, HYDROCORTISONE 0.2% CRM, OR BETAMETHASONE (0.05% LTN, 0.1% CRM) IN THE PAST 120 DAYS
DERMATOLOGY - ANTIINFLAMMATORY	FLURANDRENOLIDE	FLURANDRENOLIDE	0.05 %	CREAM (G)	TOPICAL	GENERIC/MSB	1	S=1	NONE	A=ST	Low Net Cost Strategy		ST: TRIAL OF 1 OF THE FOLLOWING: FLUTICASONE 0.05% CRM, TRIAMCINOLONE (0.1% LTN, 0.025% OINT), DESONIDE 0.05% OINT, HYDROCORTISONE 0.2% CRM, OR BETAMETHASONE (0.05% LTN, 0.1% CRM) IN THE PAST 120 DAYS
DERMATOLOGY - ANTIINFLAMMATORY	HYDROCORTISONE BUTYRATE	HYDROCORTISONE BUTYRATE	0.1 %	OINT. (G)	TOPICAL	GENERIC/MSB	1	S=1	NONE	A=ST	Low Net Cost Strategy		ST: TRIAL OF 1 OF THE FOLLOWING: FLUTICASONE 0.05% CRM, TRIAMCINOLONE (0.1% LTN, 0.025% OINT), DESONIDE 0.05% OINT, HYDROCORTISONE 0.2% CRM, OR BETAMETHASONE (0.05% LTN, 0.1% CRM) IN THE PAST 120 DAYS
DERMATOLOGY - ANTIINFLAMMATORY	HYDROCORTISONE BUTYRATE	HYDROCORTISONE BUTYRATE	0.1 %	LOTION	TOPICAL	GENERIC/MSB	1	S=1	NONE	A=ST	Low Net Cost Strategy		ST: TRIAL OF 1 OF THE FOLLOWING: FLUTICASONE 0.05% CRM, TRIAMCINOLONE (0.1% LTN, 0.025% OINT), DESONIDE 0.05% OINT, HYDROCORTISONE 0.2% CRM, OR BETAMETHASONE (0.05% LTN, 0.1% CRM) IN THE PAST 120 DAYS
DERMATOLOGY - ANTIINFLAMMATORY	PANDEL	HYDROCORTISONE PROBUTATE	0.1 %	CREAM (G)	TOPICAL	SSB	2	S=2	NONE	A=ST	Low Net Cost Strategy		ST: TRIAL OF 1 OF THE FOLLOWING: FLUTICASONE 0.05% CRM, TRIAMCINOLONE (0.1% LTN, 0.025% OINT), DESONIDE 0.05% OINT, HYDROCORTISONE 0.2% CRM, OR BETAMETHASONE (0.05% LTN, 0.1% CRM) IN THE PAST 120 DAYS
DERMATOLOGY - MISCELLANEOUS	QUTENZA	CAPSAICIN/SKIN CLEANSER	8 %	KIT	TOPICAL	SSB	3	S=3	PA	C=PA	Clinical/Safety Strategy		
DERMATOLOGY - PSORIASIS/EZEMA	TREMFYA	GUSELKUMAB	100 MG/ML	SYRINGE	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Trade Relations Strategy		
DERMATOLOGY - PSORIASIS/EZEMA	TREMFYA	GUSELKUMAB	100 MG/ML	AUTO INJECT	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Trade Relations Strategy		

ENDOCRINE DISORDER - OTHER	ORIAHNN	ELAGOLIX/ESTRADIOL/NORETHINDRN	300-1-0.5	CAP SEQ	ORAL	SSB	3	C=2	PA	C=PA	Trade Relations Strategy		
EYE - GENERAL DISORDERS	INVELTYS	LOTEPREDNOL ETABONATE	1 %	DROPS SUSP	OPHTHALMIC	SSB	3	S=3	QL ST	S=QL C=ST	Low Net Cost Strategy		ST: TRIAL OF TWO LOTEMAX OPHTHALMIC PRODUCTS IN THE PAST 365 DAYS
EYE - GENERAL DISORDERS	BROMSITE	BROMFENAC SODIUM	0.075 %	DROPS	OPHTHALMIC	SSB	3	S=3	NONE	A=ST	Trade Relations Strategy		ST: TRIAL OF GENERIC KETOROLAC OR DICLOFENAC OPHTHALMIC DROPS AND 1 OF THE FOLLOWING: ILEVRO OR PROLENSA IN THE PAST 365 DAYS
EYE - GENERAL DISORDERS	BROMFENAC SODIUM	BROMFENAC SODIUM	0.09 %	DROPS	OPHTHALMIC	GENERIC/MSB	1	S=1	NONE	A=ST	Low Net Cost Strategy		ST: TRIAL OF GENERIC KETOROLAC OR DICLOFENAC OPHTHALMIC DROPS IN THE PAST 120 DAYS
EYE - GENERAL DISORDERS	ACUVAIL	KETOROLAC TROMETHAMINE/PF	0.45 %	DROPERETTE	OPHTHALMIC	SSB	3	S=3	NONE	A=ST	Trade Relations Strategy		ST: TRIAL OF GENERIC KETOROLAC OR DICLOFENAC OPHTHALMIC DROPS AND 1 OF THE FOLLOWING: ILEVRO OR PROLENSA IN THE PAST 365 DAYS
EYE - GENERAL DISORDERS	NEVANAC	NEPAFENAC	0.1 %	DROPS SUSP	OPHTHALMIC	SSB	3	S=3	NONE	A=ST	Trade Relations Strategy		ST: TRIAL OF GENERIC KETOROLAC OR DICLOFENAC OPHTHALMIC DROPS AND 1 OF THE FOLLOWING: ILEVRO OR PROLENSA IN THE PAST 365 DAYS
HORMONAL DEFICIENCY	TESTOSTERONE	TESTOSTERONE	1.25G-1.62	GEL PACKET	TRANSDERM.	GENERIC/MSB	1	S=1	PA	C=PA	Clinical/Safety Strategy		
HORMONAL DEFICIENCY	TESTOSTERONE	TESTOSTERONE	2.5G-1.62%	GEL PACKET	TRANSDERM.	GENERIC/MSB	1	S=1	PA	C=PA	Clinical/Safety Strategy		
HORMONAL DEFICIENCY	TESTOSTERONE	TESTOSTERONE	20.25/1.25	GEL MD PMP	TRANSDERM.	GENERIC/MSB	1	S=1	PA	C=PA	Clinical/Safety Strategy		
HORMONAL DEFICIENCY	JATENZO	TESTOSTERONE UNDECANOATE	158 MG	CAPSULE	ORAL	SSB	3	S=3	PA	C=PA	Trade Relations Strategy		
HORMONAL DEFICIENCY	JATENZO	TESTOSTERONE UNDECANOATE	198 MG	CAPSULE	ORAL	SSB	3	S=3	PA	C=PA	Trade Relations Strategy		
HORMONAL DEFICIENCY	JATENZO	TESTOSTERONE UNDECANOATE	237 MG	CAPSULE	ORAL	SSB	3	S=3	PA	C=PA	Trade Relations Strategy		
INFLAMMATORY DISEASE	ORTIKOS	BUDESONIDE	6 MG	CAPSULE ER	ORAL	SSB	3	S=3	PA	C=PA	Clinical/Safety Strategy		
INFLAMMATORY DISEASE	ORTIKOS	BUDESONIDE	9 MG	CAPSULE ER	ORAL	SSB	3	S=3	PA	C=PA	Clinical/Safety Strategy		
INFLAMMATORY DISEASE	HAEGARDA	C1 ESTERASE INHIBITOR	2000 UNIT	VIAL	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy		
INFLAMMATORY DISEASE	HAEGARDA	C1 ESTERASE INHIBITOR	3000 UNIT	VIAL	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy		
INFLAMMATORY DISEASE	CINRYZE	C1 ESTERASE INHIBITOR	500 (5 ML)	VIAL	INTRAVEN.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy		
INFLAMMATORY DISEASE	TAKHZYRO	LANADELUMAB-FLYO	300 MG/2ML	VIAL	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy		
INFLAMMATORY DISEASE	SIMPONARIA	GOLIMUMAB	50 MG/4 ML	VIAL	INTRAVEN.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)	

INFLAMMATORY DISEASE	BENLYSTA	BELIMUMAB	120 MG	VIAL	INTRAVEN.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)	
INFLAMMATORY DISEASE	BENLYSTA	BELIMUMAB	200 MG/ML	AUTO INJECT	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy		
INFLAMMATORY DISEASE	BENLYSTA	BELIMUMAB	200 MG/ML	SYRINGE	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy		
INFLAMMATORY DISEASE	BENLYSTA	BELIMUMAB	400 MG	VIAL	INTRAVEN.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)	
INFLAMMATORY DISEASE	STELARA	USTEKINUMAB	45MG/0.5ML	VIAL	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy		
INFLAMMATORY DISEASE	STELARA	USTEKINUMAB	45MG/0.5ML	SYRINGE	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy		
INFLAMMATORY DISEASE	STELARA	USTEKINUMAB	90 MG/ML	SYRINGE	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy		
MISCELLANEOUS AGENTS	EXONDYS-51	ETEPLIRSEN	100 MG/2ML	VIAL	INTRAVEN.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)	
MISCELLANEOUS AGENTS	EXONDYS-51	ETEPLIRSEN	500MG/10ML	VIAL	INTRAVEN.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)	
MISCELLANEOUS AGENTS	VYONDYS-53	GOLODIRSEN	100 MG/2ML	VIAL	INTRAVEN.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)	
MISCELLANEOUS AGENTS	VILTEPSO	VILTOLARSEN	250 MG/5ML	VIAL	INTRAVEN.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)	
NEOPLASTIC DISEASE	ERLEADA	APALUTAMIDE	60 MG	TABLET	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy		
NEOPLASTIC DISEASE	TECENTRIQ	ATEZOLIZUMAB	1200 MG/20	VIAL	INTRAVEN.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)	
NEOPLASTIC DISEASE	TECENTRIQ	ATEZOLIZUMAB	840MG/14ML	VIAL	INTRAVEN.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)	
NEOPLASTIC DISEASE	KYPROLIS	CARFILZOMIB	10 MG	VIAL	INTRAVEN.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)	
NEOPLASTIC DISEASE	KYPROLIS	CARFILZOMIB	30 MG	VIAL	INTRAVEN.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)	
NEOPLASTIC DISEASE	KYPROLIS	CARFILZOMIB	60 MG	VIAL	INTRAVEN.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)	

NEOPLASTIC DISEASE	DARZALEX	DARATUMUMAB	100 MG/5ML	VIAL	INTRAVEN.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)	
NEOPLASTIC DISEASE	DARZALEX	DARATUMUMAB	400MG/20ML	VIAL	INTRAVEN.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)	
NEOPLASTIC DISEASE	NUBEQA	DAROLUTAMIDE	300 MG	TABLET	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy		
NEOPLASTIC DISEASE	XTANDI	ENZALUTAMIDE	40 MG	CAPSULE	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy		
NEOPLASTIC DISEASE	IMATINIB MESYLATE	IMATINIB MESYLATE	100 MG	TABLET	ORAL	GENERIC/MSB	4	S=4	PA QL	C=PA D=QL	Clinical/Safety Strategy		
NEOPLASTIC DISEASE	IMATINIB MESYLATE	IMATINIB MESYLATE	400 MG	TABLET	ORAL	GENERIC/MSB	4	S=4	PA QL	C=PA D=QL	Clinical/Safety Strategy		
NEOPLASTIC DISEASE	YERVOY	IPILIMUMAB	200MG/40ML	VIAL	INTRAVEN.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)	
NEOPLASTIC DISEASE	YERVOY	IPILIMUMAB	50 MG/10ML	VIAL	INTRAVEN.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)	
NEOPLASTIC DISEASE	OPDIVO	NIVOLUMAB	100MG/10ML	VIAL	INTRAVEN.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)	
NEOPLASTIC DISEASE	OPDIVO	NIVOLUMAB	240MG/24ML	VIAL	INTRAVEN.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)	
NEOPLASTIC DISEASE	OPDIVO	NIVOLUMAB	40 MG/4 ML	VIAL	INTRAVEN.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)	
NEOPLASTIC DISEASE	PHESGO	PERTUZUMAB-TRASTUZUMAB-HYZZXF	1200-600MG	VIAL	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)	
NEOPLASTIC DISEASE	PHESGO	PERTUZUMAB-TRASTUZUMAB-HYZZXF	600-600 MG	VIAL	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)	
NEUROLOGICAL DISEASE - MISCELLANEOUS	BAFIERTAM	MONOMETHYL FUMARATE	95 MG	CAPSULE DR	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy		
OTHER DRUGS	DOJOLVI	TRihePTANOIN	8.3KCAL/ML	LIQUID	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy		
OTHER DRUGS	DYSPOrt	ABOBOTULINUMT OXINA	300 UNIT	VIAL	INTRAMUSC.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)	
OTHER DRUGS	DYSPOrt	ABOBOTULINUMT OXINA	500 UNIT	VIAL	INTRAMUSC.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)	
OTHER DRUGS	XEOMIN	INCOBOTULINUMT OXINA	100 UNIT	VIAL	INTRAMUSC.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)	

OTHER DRUGS	XEOMIN	INCOBOTULINUMT OXINA	200 UNIT	VIAL	INTRAMUSC.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)	
OTHER DRUGS	XEOMIN	INCOBOTULINUMT OXINA	50 UNIT	VIAL	INTRAMUSC.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)	
OTHER DRUGS	NITISINONE	NITISINONE	10 MG	CAPSULE	ORAL	GENERIC/ MSB	4	S=4	PA	C=PA	Clinical/Safety Strategy		
OTHER DRUGS	NITYR	NITISINONE	10 MG	TABLET	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy		
OTHER DRUGS	NITISINONE	NITISINONE	2 MG	CAPSULE	ORAL	GENERIC/ MSB	4	S=4	PA	C=PA	Clinical/Safety Strategy		
OTHER DRUGS	NITYR	NITISINONE	2 MG	TABLET	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy		
OTHER DRUGS	ORFADIN	NITISINONE	20 MG	CAPSULE	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy		
OTHER DRUGS	ORFADIN	NITISINONE	4 MG/ML	ORAL SUSP	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy		
OTHER DRUGS	NITISINONE	NITISINONE	5 MG	CAPSULE	ORAL	GENERIC/ MSB	4	S=4	PA	C=PA	Clinical/Safety Strategy		
OTHER DRUGS	NITYR	NITISINONE	5 MG	TABLET	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy		
OTHER DRUGS	BOTOX	ONABOTULINUMT OXINA	100 UNIT	VIAL	INJECTION	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)	
OTHER DRUGS	BOTOX	ONABOTULINUMT OXINA	200 UNIT	VIAL	INJECTION	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)	
OTHER RESPIRATORY DISORDERS	OFEV	NINTEDANIB ESYLATE	100 MG	CAPSULE	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy		
OTHER RESPIRATORY DISORDERS	OFEV	NINTEDANIB ESYLATE	150 MG	CAPSULE	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy		
OTHER RESPIRATORY DISORDERS	ESBRIET	PIRFENIDONE	267 MG	CAPSULE	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy		
OTHER RESPIRATORY DISORDERS	ESBRIET	PIRFENIDONE	267 MG	TABLET	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy		
OTHER RESPIRATORY DISORDERS	ESBRIET	PIRFENIDONE	801 MG	TABLET	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy		

OTHER RESPIRATORY DISORDERS	KALYDECO	IVACAFTOR	150 MG	TABLET	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy		
OTHER RESPIRATORY DISORDERS	KALYDECO	IVACAFTOR	25 MG	GRAN PACK	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy		
OTHER RESPIRATORY DISORDERS	KALYDECO	IVACAFTOR	50 MG	GRAN PACK	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy		
OTHER RESPIRATORY DISORDERS	KALYDECO	IVACAFTOR	75 MG	GRAN PACK	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy		
PAIN MANAGEMENT - ANALGESICS	NURTEC ODT	RIMEGEPANT SULFATE	75 MG	TAB RAPDIS	ORAL	SSB	2	S=2	PA	C=PA	Trade Relations Strategy		
PAIN MANAGEMENT - ANALGESICS	UBRELVY	UBROGEPANT	100 MG	TABLET	ORAL	SSB	2	S=2	PA	C=PA	Trade Relations Strategy		
PAIN MANAGEMENT - ANALGESICS	UBRELVY	UBROGEPANT	50 MG	TABLET	ORAL	SSB	2	S=2	PA	C=PA	Trade Relations Strategy		
PAIN MANAGEMENT - ANALGESICS	REYVOW	LASMIDITAN SUCCINATE	100 MG	TABLET	ORAL	SSB	2	S=2	PA	C=PA	Trade Relations Strategy		
PAIN MANAGEMENT - ANALGESICS	REYVOW	LASMIDITAN SUCCINATE	50 MG	TABLET	ORAL	SSB	2	S=2	PA	C=PA	Trade Relations Strategy		
PARKINSONS DISEASE	ONGENTYS	OPICAPONE	50 MG	CAPSULE	ORAL	SSB	3	S=3	PA	C=PA	Clinical/Safety Strategy		
SEIZURE DISORDER	EPIDIOLEX	CANNABIDIOL (CBD)	100 MG/ML	SOLUTION	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy		
UPPER GASTROINTESTINAL DISORDERS - ULCER DISEASE	GIMOTI	METOCLOPRAMIDE HCL	15MG/SPRAY	SPRAY/PUMP	NASAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy		
WEIGHT REDUCTION	QSYMIA	PHENTERMINE/TOPIRAMATE	11.25-69MG	CPMP 24HR	ORAL	SSB	3	S=3	PA	C=PA	Trade Relations Strategy	Antiobesity	
WEIGHT REDUCTION	QSYMIA	PHENTERMINE/TOPIRAMATE	15 MG-92MG	CPMP 24HR	ORAL	SSB	3	S=3	PA	C=PA	Trade Relations Strategy	Antiobesity	

WEIGHT REDUCTION	QSYMIA	PHENTERMINE/TOPIRAMATE	3.75-23 MG	CPMP 24HR	ORAL	SSB	3	S=3	PA	C=PA	Trade Relations Strategy	Antiobesity	
WEIGHT REDUCTION	QSYMIA	PHENTERMINE/TOPIRAMATE	7.5MG-46MG	CPMP 24HR	ORAL	SSB	3	S=3	PA	C=PA	Trade Relations Strategy	Antiobesity	
WEIGHT REDUCTION	SAXENDA	LIRAGLUTIDE	3 MG/0.5ML	PEN INJCTR	SUBCUTANE.	SSB	3	C=2	PA	C=PA	Trade Relations Strategy	Antiobesity	
WEIGHT REDUCTION	BELVIQ	LORCASERIN HCL	10 MG	TABLET	ORAL	SSB	3	S=3	PA	C=PA	Trade Relations Strategy	Antiobesity	
WEIGHT REDUCTION	BELVIQ XR	LORCASERIN HCL	20 MG	TAB ER 24H	ORAL	SSB	3	S=3	PA	C=PA	Trade Relations Strategy	Antiobesity	

4Q20 MedImpact Managed Formulary Actions

Additions and/or Revisions effective: 1/1/2021
Deletions effective: 1/1/2021 for NEW member prescriptions
Grandfather until 4/1/2021 for EXISTING member prescriptions

RATIONALE OF CHANGES

Trade Relations Strategy

Approach based on a financial review to deliver low net cost opportunities through pharmaceutical manufacture agreement strategies while taking into consideration the expected market share shift, future pipeline products, member impact and plan impact.

Low Net Cost Strategy

Delivering cost-efficient and clinically appropriate formulary content to meet the pharmacy benefit management needs of MedImpact clients; including appropriate development of preferred drug lists with consideration of low net cost strategies that includes MAC lists, non-pharmaceutical manufacture agreement strategies, and other cost management tools.

Clinical/Safety Strategy

Delivering cost-efficient and clinically appropriate formulary content to promote member safety and savings through the evaluation of scientific evidence, standards of practice, peer-reviewed medical literature, clinical practice guidelines, and guidance from the U.S. Food and Drug Administration (FDA)/Center for Disease Control (CDC).

Regulatory Update

Formulary/utilization management changes to comply with federal and/or state statutes, regulations, rules and policy requirements that pertain to the administration of the pharmacy benefit.

LEGEND

Note: The drug names listed are for reference purposes and denote action on the chemical entity unless otherwise specified. Where generic and brand products for a chemical entity co-exist, coverage and copayment for each will be a function of plan benefit design.

FORMULARY		UTILIZATION MANAGEMENT (UM)		OPTIONAL BENEFIT EXCLUSION
Formulary Status	Formulary Actions	UM Definition	UM Actions	Coverage for each category will be a function of plan
F = Formulary	C = Change	AGE = Age restriction	A = Add UM	Antiobesity
NF = Non-Formulary	S = Sustain	QL = Quantity Limit	D = Delete UM	Cosmetic Indications
E = Excluded		ST = Step Therapy	C = Change UM	Dietary Supplements and Non-Drug Products
NC = Not covered		CU = Concurrent Use edit	E = Excluded drug from formulary	Erectile Dysfunction
		PA = Prior Authorization	S = Sustain UM	Infertility
				Medical Foods: Dietary supplements, Enteral Feeding, Infant formula
				Non-Self Administered Drug (NSA)
				Ostomy Supplies
				Class O = Over the Counter Products
				Class Q = Products that are neither drugs nor devices, such as dietary supplements (including prenatal and other vitamins), medical foods, herbal preparations, and bulk flavorings or colorants